William R. Rohn Appointed to Hansen Medical’s Board of Directors

MOUNTAIN VIEW, CA--(Marketwire - March 27, 2012) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible catheter robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced William R. Rohn has been appointed as a Director and elected to chair the Compensation Committee, effective immediately. The appointment increases board membership to eight. Mr. Rohn brings to the board significant experience from his over 40 years of executive management in the healthcare industry.

“Bill has broad business development, commercial and operational experience in the healthcare industry, and the expertise he has acquired through past and present executive and directorship positions will augment the Company’s strong knowledge base, and support continued growth for Hansen’s flexible robotic technology in both EP and vascular applications,” said Bruce Barclay, President and Chief Executive Officer.

Mr. Rohn has extensive healthcare experience, having previously served as Chief Operating Officer of Biogen Idec, a leading biopharmaceutical firm specializing in drug treatments for neurodegenerative diseases. During his tenure, he was responsible for commercial operations, medical affairs, manufacturing, quality and international operations. In addition to his operational oversight, he also furthered the company’s development and pipeline review, strategic opportunities and corporate compliance. Prior to its merger with Biogen in 2003, Mr. Rohn served as President and Chief Operating Officer at Idec Pharmaceuticals Corporation where he oversaw the company’s initial commercial infrastructure build-out in support of its launch of Rituxan®, the first monoclonal antibody approved in the United States for the treatment of cancer. Preceding his term at Biogen Idec, Mr. Rohn served eight years at Adria Laboratories, an oncology pharmaceutical development company, most recently as Senior Vice President of Commercial Operations.

Mr. Rohn has also served as a Director of a number of boards of both public and private healthcare companies including Elan Corp. plc, Intellikine and Cerus Corporation. He currently serves on the boards of Protox Therapeutics, Inc., The La Jolla Institute for Allergy and Immunology and Cebix Inc.

“Hansen Medical is at the forefront of innovation in flexible robotics, and I am pleased to join the Hansen board during these exciting times,” remarked Mr. Rohn on his appointment.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company’s Sensei® X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei X System and Artisan Control Catheter are cleared for use during EP procedures, such as guiding catheters in the treatment of AF, and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. The Company’s Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone conformity assessment and CE marking and are commercially available in the European Union.

In the U.S., the Magellan™ Robotic System, the NorthStar™ Robotic Catheter and accessories are the subject of a current filing with the FDA and are not commercially available. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, expectations, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” goal,” “estimate,” “anticipates”, and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the anticipated growth of Hansen’s flexible robotic technology in both EP and vascular applications . Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory and sales challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the uncertain timelines, costs and results of pre-clinical and clinical trials; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; the effect of credit, financial and economic conditions on capital spending by our potential customers; our ability to manage expenses and obtain additional financing; and other risks more fully described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on March 15, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), and Sensei are registered trademarks of Hansen Medical, Inc. in the United States and other countries.